Novel therapeutic targets in neuropsychiatric disorders: The neuroepigenome

Current Pharmaceutical Design

Volumn 20, Issue 11, 2014, Pages 1831-1839

  Tremolizzo, Lucio ^a   Rodriguez Menendez, Virginia ^a   Conti, Elisa ^a   Zoia, Chiara Paola ^a   Cavaletti, Guido ^a   Ferrarese, Carlo ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

DNA methylation; Histone deacetylase; Neuroepigenome; Neuropsychiatric disorders

Indexed keywords

DNA; HISTONE; HISTONE DEACETYLASE INHIBITOR; PSYCHOTROPIC AGENT;

ALZHEIMER DISEASE; DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; GENOME; GENOTYPE ENVIRONMENT INTERACTION; HISTONE ACETYLATION; HUMAN; MENTAL DISEASE; MOLECULAR PATHOLOGY; MOTOR DYSFUNCTION; NERVE CELL PLASTICITY; NERVOUS SYSTEM FUNCTION; NEUROPATHOLOGY; NEUROPATHY; NEUROPSYCHIATRY; NONHUMAN; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; PSYCHOPHARMACOTHERAPY; REVIEW; SCHIZOPHRENIA; TRINUCLEOTIDE REPEAT; ANIMAL; DRUG DESIGN; GENETIC EPIGENESIS; GENETICS; MENTAL DISORDERS; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PROCEDURES;

ANIMALS; DRUG DESIGN; EPIGENESIS, GENETIC; EPIGENOMICS; HUMANS; MENTAL DISORDERS; MOLECULAR TARGETED THERAPY; NEUROPSYCHIATRY;

EID: 84900802721     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990535     Document Type: Review

References (172)

1. Berger SL. The complex language of chromatin regulation during transcription. Nature 2007; 447: 407-12.
2. Martín-Subero JI. How epigenomics brings phenotype into being. Pediatr Endocrinol Rev 2011; 9(Suppl.1): 506-10.
3. Weaver IC, Cervoni N, Champagne FA, et al. Epigenetic programming by maternal behavior. Nat Neurosci 2004; 7: 847-54.
4. Weaver IC. Epigenetic programming by maternal behavior and pharmacological intervention. Nature versus nurture: let's call the whole thing off. Epigenetics 2007; 2: 22-8.
5. Feinberg AP. Phenotypic plasticity and the epigenetics of human disease. Nature 2007; 447: 433-40.
6. Haggarty SJ, Tsai LH. Probing the role of HDACs and mechanisms of chromatin-mediated neuroplasticity. Neurobiol Learn Mem 2011; 96: 41-52.
7. You JS, Jones PA. Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012; 22: 9-20.
8. Simonini MV, Camargo LM, Dong E, et al. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci USA 2006; 103: 1587-92.
9. Burton BS. On the propyl derivatives and decomposition products of ethylacetoacetate. Am Chem J. 1882; 3: 385-95.
10. Meunier H, Carraz G, Meunier Y, Eymard P, Aimard M. Propriétés pharmacodynamiques de l'Acide n-dipropylacetique. Therapie 1963; 18: 435-38.
11. Perucca E. Pharmacological and therapeutic properties of valproate: a summary after 35 years of clinical experience. CNS Drugs 2002; 16: 695-714.
12. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-41.
13. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16: 669-94.
14. Tung EW, Winn LM. Epigenetic modifications in valproic acidinduced teratogenesis. Toxicol Appl Pharmacol 2010; 248: 201-9.
15. Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol 2010; 2010. pii, 479364.
16. Tremolizzo L, Doueiri MS, Dong E, et al. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry 2005; 57: 500-9.
17. Tremolizzo L, Rodriguez-Menendez V, DiFrancesco JC, et al. Huntington's disease and HDACi: would sulpiride and valproate be of therapeutic value? Med Hypotheses 2007; 69: 964-5.
18. Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 2004; 64: 1079-86.
19. Tremolizzo L, Difrancesco JC, Rodriguez-Menendez V, et al. Valproate induces epigenetic modifications in lymphomonocytes from epileptic patients. Prog Neuropsychopharmacol Biol Psychiatry 2012; 39: 47-51.
20. Turnbull DM, Rawlins MD, Weightman D, Chadwick DW. Plasma concentrations of sodium valproate: their clinical value. Ann Neurol 1983; 14: 38-42.
21. Blaheta RA, Michaelis M, Driever PH, Cinatl Jr J. Evolving anticancer drug valproic acid: insights into the mechanism and clinical studies. Med Res Rev 2005; 25: 383-97.
22. Tsai HC, Wei KC, Tsai CN, et al. Effect of valproic acid on the outcome of glioblastoma multiforme. Br J Neurosurg 2012; 26: 347-54.
23. Hoffmann K, Czapp M, Loscher W. Increase in antiepileptic efficacy during prolonged treatment with valproic acid: role of inhibition of histone deacetylases? Epilepsy Res 2008; 81: 107-13.
24. Stapleton SL, Thompson PA, Ou CN, et al. Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates. Cancer Chemother Pharmacol 2008; 61: 647-52.
25. Eyal S, Yagen B, Sobol E, Altschuler Y, Shmuel M, Bialer M. The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 2004; 45: 737-44.
26. Perisic T, Zimmermann N, Kirmeier T, et al. Valproate and amitriptyline exert common and divergent influences on global and gene promoter specific chromatin modifications in rat primary astrocytes. Neuropsychopharmacology 2010; 35: 792-805.
27. Costa E, Chen Y, Davis J, et al. Reelin and schizophrenia: a disease at the interface of the genome and the epigenome. Mol Interv 2002; 2: 47-57.
28. Tremolizzo L, Carboni G, Ruzicka WB, et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci USA 2002; 99: 17095-100.
29. Weaver IC, Champagne FA, Brown SE, et al. Reversal of maternal programming of stress responses in adult offspring through methyl supplementation: altering epigenetic marking later in life. J Neurosci 2005; 25: 11045-54.
30. Toyokawa S, Uddin M, Koenen KC, Galea S. How does the social environment 'get into the mind'? Epigenetics at the intersection of social and psychiatric epidemiology. Soc Sci Med 2012; 74: 67-74.
31. Veldic M, Guidotti A, Maloku E, Davis JM, Costa E. In psychosis, cortical interneurons overexpress DNA-methyltransferase 1. Proc Natl Acad Sci USA 2005; 102: 2152-7.
32. Ruzicka WB, Zhubi A, Veldic M, Grayson DR, Costa E, Guidotti A. Selective epigenetic alteration of layer I GABAergic neurons isolated from prefrontal cortex of schizophrenia patients using laser-assisted microdissection. Mol Psychiatry 2007; 12: 385-97.
33. Costa E, Grayson DR, Mitchell CP, Tremolizzo L, Veldic M, Guidotti A. GABAergic cortical neuron chromatin as a putative target to treat schizophrenia vulnerability. Crit Rev Neurobiol 2003; 15: 121-42.
34. Costa E, Dong E, Grayson DR, Guidotti A, Ruzicka W, Veldic M. Reviewing the role of DNA (cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics 2007; 2: 29-36.
35. Halpain S. Actin and the agile spine: how and why do dendritic spines dance? Trends Neurosci 2000; 23: 141-6.
36. Costa E, Davis JM, Dong E, et al. A GABAergic cortical deficit dominates schizophrenia pathophysiology. Crit Rev Neurobiol 2004; 16: 1-23.
37. Guidotti A, Grayson DR. A neurochemical basis for an epigenetic vision of psychiatric disorders (1994-2009). Pharmacol Res 2011; 64: 344-9.
38. Dong E, Caruncho H, Liu WS, et al. A reelin-integrin receptor interaction regulates Arc mRNA translation in synaptoneurosomes. Proc Natl Acad Sci USA 2003; 100: 5479-84.
39. Falconer DS. 2 new mutants, trembler and reeler, with neurological actions in the house mouse (mus-musculus l). J Genet 1951; 50: 192-201.
40. D'Arcangelo G, Miao GG, Chen SC, Soares HD, Morgan JI, Curran T. A protein related to extracellular matrix proteins deleted in the mouse mutant reeler. Nature 1995; 374: 719-23.
41. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636-45.
42. Tueting P, Costa E, Dwivedi Y, et al. The phenotypic characteristics of heterozygous reeler mouse. Neuroreport 1999; 10: 1329-34.
43. Pappas GD, Kriho V, Liu WS, Tremolizzo L, Lugli G, Larson J. Immunocytochemical localization of reelin in the olfactory bulb of the heterozygous reeler mouse: an animal model for schizophrenia. Neurol Res 2003; 25: 819-30.
44. Costa E, Davis J, Pesold C, Tueting P, Guidotti A. The heterozygote reeler mouse as a model for the development of a new generation of antipsychotics. Curr Opin Pharmacol 2002; 2: 56-62.
45. Impagnatiello F, Guidotti AR, Pesold C, et al. A decrease of reelin expression as a putative vulnerability factor in schizophrenia. Proc Natl Acad Sci USA 1998; 95: 15718-23.
46. Grayson DR, Jia X, Chen Y, et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci USA 2005; 102: 9341-6.
47. Antun FT, Burnett GB, Cooper AJ, Daly RJ, Smythies JR, Zealley AK. The effects of L-methionine (without MAOI) in schizophrenia. J Psychiatry Res 1971; 8: 63-71.
48. Dong E, Chen Y, Gavin DP, Grayson DR, Guidotti A. Valproate induces DNA demethylation in nuclear extracts from adult mouse brain. Epigenetics 2010; 5: 730-5.
49. Dong E, Nelson M, Grayson DR, Costa E, Guidotti A. Clozapine and sulpiride but not haloperidol or olanzapine activate brain DNA demethylation. Proc Natl Acad Sci USA 2008; 105: 13614-9.
50. Guidotti A, Dong E, Kundakovic M, Satta R, Grayson DR, Costa E. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol Sci 2009; 30: 55-60.
51. Roth TL, Lubin FD, Sodhi M, Kleinman JE. Epigenetic mechanisms in schizophrenia. Biochim Biophys Acta 2009; 1790: 869-77.
52. Chen Y, Dong E, Grayson DR. Analysis of the GAD1 promoter: trans-acting factors and DNA methylation converge on the 5' untranslated region. Neuropharmacology 2011; 60: 1075-87.
53. Woods BT. Is schizophrenia a progressive neurodevelopmental disorder? Toward a unitary pathogenetic mechanism. Am J Psychiatry 1998; 155: 1661-70.
54. Sandner G, Host L, Angst MJ, Guiberteau T, Guignard B, Zwiller J. The HDAC Inhibitor Phenylbutyrate Reverses Effects of Neonatal Ventral Hippocampal Lesion in Rats. Front Psychiatry 2011; 1: 153.
55. Connor CM, Dincer A, Straubhaar J, Galler JR, Houston IB, Akbarian S. Maternal immune activation alters behavior in adult offspring, with subtle changes in the cortical transcriptome and epigenome. Schizophr Res 2012 Jul 15. [Epub ahead of print].
56. Zhang TY, Hellstrom IC, Bagot RC, Wen X, Diorio J, Meaney MJ. Maternal care and DNA methylation of a glutamic acid decarboxylase 1 promoter in rat hippocampus. J Neurosci 2010; 30: 13130-7.
57. Gavin DP, Akbarian S. Epigenetic and post-transcriptional dysregulation of gene expression in schizophrenia and related disease. Neurobiol Dis 2012; 46: 255-62.
58. Haddad PM, Das A, Ashfaq M, Wieck A. A review of valproate in psychiatric practice. Expert Opin Drug Metab Toxicol 2009; 5: 539-51.
59. Müller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group. J Clin Psychopharmacol 2000; 20: 195-203.
60. Grayson DR, Kundakovic M, Sharma RP. Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders? Mol Pharmacol 2010; 77: 126-35.
61. Conti E, Galimberti G, Piazza F, Raggi ME, Ferrarese C. Increased soluble APPalpha, Abeta 1-42, and anti-Abeta 1-42 antibodies in plasma from down syndrome patients. Alzheimer Dis Assoc Disord 2010; 24: 96-100.
62. Chouliaras L, Rutten BP, Kenis G, et al. Epigenetic regulation in the pathophysiology of Alzheimer's disease. Prog Neurobiol 2010; 90: 498-510.
63. Zawia NH, Lahiri DK, Cardozo-Pelaez F. Epigenetics, oxidative stress, and Alzheimer disease. Free Radic Biol Med 2009; 46: 1241-9.
64. Barrachina M, Ferrer I. DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain. J Neuropathol Exp Neurol 2009; 68: 880-91.
65. Drake J, Petroze R, Castegna A, et al. 4-Hydroxynonenal oxidatively modifies histones: implications for Alzheimer's disease. Neurosci Lett 2004; 356: 155-8.
66. Miller G. Epigenetics. A role for epigenetics in cognition. Science 2010; 329: 27.
67. Bihaqi SW, Schumacher A, Maloney B, Lahiri DK, Zawia NH. Do epigenetic pathways initiate late onset alzheimer disease (LOAD): towards a new paradigm. Curr Alzheimer Res 2012; 9: 574-88.
68. Gräff J, Rei D, Guan JS, et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012; 483: 222-6.
69. Bandyopadhyay D, Medrano EE. The emerging role of epigenetics in cellular and organismal aging. Exp Gerontol 2003; 38: 1299-307.
70. Fraga MF, Esteller M. Epigenetics and aging: the targets and the marks. Trends Genet 2007; 23: 413-8.
71. Liu L, Wylie RC, Andrews LG, Tollefsbol TO. Aging, cancer and nutrition: the DNA methylation connection. Mech Ageing Dev 2003; 124: 989-98.
72. Poulsen P, Esteller M, Vaag A, Fraga MF. The epigenetic basis of twin discordance in age-related diseases. Pediatr Res 2007; 61: R38-42.
73. Wilson VL, Jones PA. DNA methylation decreases in aging but not in immortal cells. Science 1983; 220: 1055-7.
74. Ulrey CL, Liu L, Andrews LG, Tollefsbol TO. The impact of metabolism on DNA methylation. Hum Mol Genet 2005; 14(S1): R139-47.
75. Chiang PK, Gordon RK, Tal J, et al. S-Adenosylmethionine and methylation. FASEB J 1996; 10: 471-80.
76. Lee ME, Wang H. Homocysteine and hypomethylation. A novel link to vascular disease, Trends Cardiovasc Med 1999; 9: 49-54.
77. Fuso A, Scarpa S. One-carbon metabolism and Alzheimer's disease: is it all a methylation matter? Neurobiol Aging 2011; 32: 1192-5.
78. Doecke JD, Laws SM, Faux NG, et al. Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. Arch Neurol 2012 Jul 16: 1-8. doi: 10.1001/archneurol.2012.1282. [Epub ahead of print].
79. Galimberti G, Conti E, Zini M, et al. Post-methionine load test: A more sensitive tool to reveal hyperhomocysteinemia in Alzheimer patients? Clin Biochem 2008; 41: 914-6.
80. Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. Nat Rev Neurosci 2011; 12: 723-38.
81. Scarpa S, Fuso A, D'Anselmi F, Cavallaro RA. Presenilin 1 gene silencing by S-adenosylmethionine: a treatment for Alzheimer disease? FEBS Lett 2003; 541: 145-8.
82. Fuso A, Seminara L, Cavallaro RA, D'Anselmi F, Scarpa S. Sadenosylmethionine/ homocysteine cycle alterations modify DNA methylation status with consequent deregulation of PS1 and BACE and beta-amyloid production. Mol Cell Neurosci 2005; 28: 195-204.
83. Fuso A, Nicolia V, Cavallaro RA, Scarpa S. DNA methylase and demethylase activities are modulated by one-carbon metabolism in Alzheimer's disease models. J Nutr Biochem 2011; 22: 242-51.
84. Fuso A, Cavallaro RA, Zampelli A, et al. Gamma-Secretase is differentially modulated by alterations of homocysteine cycle in neuroblastoma and glioblastoma cells. J Alzheimers Dis 2007; 11: 275-90.
85. Fuso A, Nicolia V, Cavallaro RA, et al. B-vitamin deprivation induces hyperhomocysteinemia and brain S-adenosylhomocysteine, depletes brain S-adenosylmethionine, and enhances PS1 and BACE expression and amyloid-beta deposition in mice. Mol Cell Neurosci 2008; 37: 731-46.
86. Fuso A, Nicolia V, Ricceri L, et al. S-adenosylmethionine reduces the progress of the Alzheimer-like features induced by B-vitamin deficiency in mice. Neurobiol Aging 2012; 33: 1482.e1-16.
87. Scarpa S, Cavallaro RA, D'Anselmi F, Fuso A. Gene silencing through methylation: an epigenetic intervention on Alzheimer disease. J Alzheimers Dis 2006; 9: 407-14.
88. Lee S, Lemere CA, Frost JL, Shea TB. Dietary supplementation with S-adenosyl methionine delayed amyloid-_ and tau pathology in 3xTg-AD mice. J Alzheimers Dis 2012; 28: 423-31.
89. Linnebank M, Popp J, Smulders Y, et al. S-adenosylmethionine is decreased in the cerebrospinal fluid of patients with Alzheimer's disease. Neurodegener Dis 2010; 7: 373-8.
90. Panza F, Frisardi V, Capurso C, et al. Possible role of Sadenosylmethionine, S-adenosylhomocysteine, and polyunsaturated fatty acids in predementia syndromes and Alzheimer's disease. J Alzheimers Dis 2009; 16: 467-70.
91. Shea TB, Chan A. S-adenosyl methionine: a natural therapeutic agent effective against multiple hallmarks and risk factors associated with Alzheimer's disease. J Alzheimers Dis 2008; 13: 67-70.
92. He F, Todd PK. Epigenetics in nucleotide repeat expansion disorders. Semin Neurol 2011; 31: 470-83.
93. Wang YH, Gellibolian R, Shimizu M, Wells RD, Griffith J. Long CCG triplet repeat blocks exclude nucleosomes: a possible mechanism for the nature of fragile sites in chromosomes. J Mol Biol 1996; 263: 511-6.
94. Chiurazzi P, Pomponi MG, Willemsen R, Oostra BA, Neri G. In vitro reactivation of the FMR1 gene involved in fragile X syndrome. Hum Mol Genet 1998; 7: 109-13.
95. Nucifora FC Jr, Sasaki M, Peters MF, et al. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science 2001; 291: 2423-8.
96. Kwok RP, Lundblad JR, Chrivia JC, et al. Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 1994; 370: 223-6.
97. Butler R, Bates GP. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci 2006; 7: 784-96.
98. Hoshino M, Tagawa K, Okuda T, et al. Histone deacetylase activity is retained in primary neurons expressing mutant huntingtin protein. J Neurochem 2003; 87: 257-67.
99. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001; 413: 739-43.
100. Gaub P, Tedeschi A, Puttagunta R, Nguyen T, Schmandke A, Di Giovanni S. HDAC inhibition promotes neuronal outgrowth and counteracts growth cone collapse through CBP/p300 and P/CAFdependent p53 acetylation. Cell Death Differ 2010; 17: 1392-408.
101. Pallos J, Bodai L, Lukacsovich T, et al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease. Hum Mol Genet 2008; 17: 3767-75.
102. Bates EA, Victor M, Jones AK, Shi Y, Hart AC. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J Neurosci 2006; 26: 2830-8.
103. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003; 100: 2041-6.
104. Ma C, D'Mello SR. Neuroprotection by histone deacetylase-7 (HDAC7) occurs by inhibition of c-jun expression through a deacetylase-independent mechanism. J Biol Chem 2011; 286: 4819-28.
105. Benn CL, Butler R, Mariner L, et al. Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease. PLoS One 2009; 4: e5747.
106. Mielcarek M, Benn CL, Franklin SA, et al. SAHA decreases HDAC 2 and 4 levels in vivo and improves molecular phenotypes in the R6/2 mouse model of Huntington's disease. PLoS One 2011; 6: e27746.
107. Thomas EA, Coppola G, Desplats PA, et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA 2008; 105: 15564-9.
108. Hathorn T, Snyder-Keller A, Messer A. Nicotinamide improves motor deficits and upregulates PGC-1_ and BDNF gene expression in a mouse model of Huntington's disease. Neurobiol Dis 2011; 41: 43-50.
109. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003; 23: 9418-27.
110. Ebbel EN, Leymarie N, Schiavo S, et al. Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry. Anal Biochem 2010; 399: 152-61.
111. Sadri-Vakili G, Cha JH. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). Curr Alzheimer Res 2006; 3: 403-8.
112. Sadri-Vakili G, Bouzou B, Benn CL, et al. Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum Mol Genet 2007; 16: 1293-306.
113. Oliveira JM, Chen S, Almeida S, et al. Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J Neurosci 2006 Oct 25; 26(43): 11174-86.
114. Dompierre JP, Godin JD, Charrin BC, et al. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci 2007; 27: 3571-83.
115. Bobrowska A, Paganetti P, Matthias P, Bates GP. Hdac6 knock-out increases tubulin acetylation but does not modify disease progression in the R6/2 mouse model of Huntington's disease. PLoS One 2011; 6: e20696.
116. McConoughey SJ, Basso M, Niatsetskaya ZV, et al. Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Mol Med 2010; 2: 349-70.
117. Minamiyama M, Katsuno M, Adachi H, et al. Sodium butyrate ameliorates phenotypic expression in a transgenic mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 2004; 13: 1183-92.
118. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006; 2: 551-8.
119. Wong JC, Hong R, Schreiber SL. Structural biasing elements for in-cell histone deacetylase paralog selectivity. J Am Chem Soc 2003; 125: 5586-7.
120. Rai M, Soragni E, Jenssen K, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One 2008; 3: e1958.
121. Rai M, Soragni E, Chou CJ, et al. Two new pimelic diphenylamide HDAC inhibitors induce sustained frataxin upregulation in cells from Friedreich's ataxia patients and in a mouse model. PLoS One 2010; 5: e8825.
122. Sandi C, Pinto RM, Al-Mahdawi S, et al. Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model. Neurobiol Dis 2011; 42: 496-505.
123. Todd PK, Oh SY, Krans A, et al. Histone deacetylases suppress CGG repeat-induced neurodegeneration via transcriptional silencing in models of fragile X tremor ataxia syndrome. PLoS Genet 2010; 6: e1001240.
124. Harder A, Titze S, Herbst L, et al. Monozygotic twins with neurofibromatosis type 1 (NF1) display differences in methylation of NF1 gene promoter elements, 5' untranslated region, exon and intron 1. Twin Res Hum Genet 2010; 13: 582-94.
125. Feber A, Wilson GA, Zhang L, et al. Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. Genome Res 2011; 21: 515-24.
126. Uchida H, Ma L, Ueda H. Epigenetic gene silencing underlies Cfiber dysfunctions in neuropathic pain. J Neurosci 2010; 30: 4806-14.
127. Popko B. Epigenetic control of myelin repair. Nat Neurosci 2008; 11: 987-8.
128. Jacob C, Lebrun-Julien F, Suter U. How histone deacetylases control myelination. Mol Neurobiol 2011; 44: 303-12.
129. Pereira JA, Lebrun-Julien F, Suter U. Molecular mechanisms regulating myelination in the peripheral nervous system. Trends Neurosci 2012; 35: 123-34.
130. Boshnjaku V, Ichi S, Shen YW, et al. Epigenetic regulation of sensory neurogenesis in the dorsal root ganglion cell line ND7 by folic acid. Epigenetics 2011; 6: 1207-16.
131. Rodriguez-Menendez V, Tremolizzo L, Cavaletti G. Targeting cancer and neuropathy with histone deacetylase inhibitors: two birds with one stone? Curr Cancer Drug Targets 2008; 8: 266-74.
132. d'Ydewalle C, Bogaert E, Van Den Bosch L.HDAC6 at the Intersection of Neuroprotection and Neurodegeneration. Traffic 2012; 13: 771-9.
133. Rodriguez-Menendez V, Gilardini A, Bossi M, et al. Valproate protective effects on cisplatin-induced peripheral neuropathy: an in vitro and in vivo study. Anticancer Res 2008; 28: 335-42.
134. Watanabe T, Nagase K, Chosa M, Tobinai K. Schwann cell autophagy induced by SAHA, 17-AAG, or clonazepam can reduce bortezomib-induced peripheral neuropathy. Br J Cancer 2010; 103: 1580-7.
135. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Expert Opin Drug Saf 2004; 3: 535-46.
136. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011; 76: 1758-65.
137. Chiechio S, Zammataro M, Morales ME, et al. Epigenetic modulation of mGlu2 receptors by histone deacetylase inhibitors in the treatment of inflammatory pain. Mol Pharmacol 2009; 75: 1014-20.
138. Kiguchi N, Kobayashi Y, Maeda T, et al. Epigenetic augmentation of the macrophage inflammatory protein 2/C-X-C chemokine receptor type 2 axis through histone H3 acetylation in injured peripheral nerves elicits neuropathic pain. J Pharmacol Exp Ther 2012; 340: 577-87.
139. Uchida H, Sasaki K, Ma L, Ueda H. Neuron-restrictive silencer factor causes epigenetic silencing of Kv4.3 gene after peripheral nerve injury. Neuroscience 2010; 166: 1-4.
140. De Grandis D, Minardi C. Acetyl-L-carnitine (levacecarnine) in the treatment of diabetic neuropathy. A long-term randomized, doubleblind, placebo-controlled study. Drugs R.D 2002; 3: 223-31.
141. Sima AA. Acetyl-L-carnitine in diabetic polyneuropathy: experimental and clinical data. CNS Drugs 2007; 21: 13-23.
142. Sima AA, Calvani M, Mehra M, Amato A. Acetyl-L-Carnitine Study Group. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy: an analysis of two randomized placebo-controlled trials. Diabetes Care 2005; 28: 89-94.
143. Youle M, Osio M, ALCAR Study Group. A double-blind, parallelgroup, placebo-controlled, multicentre study of acetyl L-carnitine in the symptomatic treatment of antiretroviral toxic neuropathy in patients with HIV-1 infection. HIV Med 2007; 8: 241-50.
144. Maestri, A, De Pasquale Ceratti A, Cundari S, Zanna C, Cortesi E, Crino L. A pilot study on the effect of acetyl-L-carnitine in paclitaxel-and cisplatin-induced peripheral neuropathy. Tumori 2005; 91: 135-8.
145. Chiechio S, Copani A, Gereau RW 4th, Nicoletti F. Acetyl-Lcarnitine in neuropathic pain: experimental data. CNS Drugs 2007; 21: 31-8.
146. Pisano C, Pratesi G, Laccabue D, et al. Paclitaxel and Cisplatininduced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res 2003; 9: 5756-67.
147. Tabolacci E, Pietrobono R, Moscato U, Oostra BA, Chiurazzi P, Neri G. Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments. Eur J Hum Genet 2005; 13: 641-8.
148. Wang Y, Liu C, Guo QL, et al. Intrathecal 5-azacytidine inhibits global DNA methylation and methyl-CpG-binding protein 2 expression and alleviates neuropathic pain in rats following chronic constriction injury. Brain Res 2011; 1418: 64-9.
149. Chestnut BA, Chang Q, Price A, Lesuisse C, Wong M, Martin LJ. Epigenetic regulation of motor neuron cell death through DNA methylation. J Neurosci 2011; 31: 16619-36.
150. Tremolizzo L, Rodriguez-Menendez V, Sala G, Di Francesco JC, Ferrarese C. Valproate and HDAC inhibition: a new epigenetic strategy to mitigate phenotypic severity in ALS? Amyotroph Lateral Scler Other Motor Neuron Disord 2005; 6: 185-6.
151. Ryu H, Smith K, Camelo SI, et al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J Neurochem 2005; 93: 1087-98.
152. Yoo YE, Ko CP. Treatment with trichostatin A initiated after disease onset delays disease progression and increases survival in a mouse model of amyotrophic lateral sclerosis. Exp Neurol 2011; 231: 147-59.
153. Sugai F, Yamamoto Y, Miyaguchi K, et al. Benefit of valproic acid in suppressing disease progression of ALS model mice. Eur J Neurosci 2004; 20: 3179-83.
154. Rouaux C, Panteleeva I, René F, et al. Sodium valproate exerts neuroprotective effects in vivo through CREB-binding proteindependent mechanisms but does not improve survival in an amyotrophic lateral sclerosis mouse model. J Neurosci 2007; 27: 5535-45.
155. Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 2008; 155: 567-72.
156. Piepers S, Veldink JH, de Jong SW, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol 2009; 66: 227-34.
157. Contestabile A. Amyotrophic lateral sclerosis: from research to therapeutic attempts and therapeutic perspectives. Curr Med Chem 2011; 18: 5655-65.
158. Hirahara K, Vahedi G, Ghoreschi K, et al. Helper T-cell differentiation and plasticity: insights from epigenetics. Immunology 2011; 134: 235-45.
159. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron 2006; 52: 61-76.
160. Kurtuncu M. Multiple sclerosis: Could it be an epigenetic disease? Med Hypotheses 2008; 71: 945-7.
161. Kaliszewska A, De Jager PL. Exploring the role of the epigenome in multiple sclerosis: A window onto cell-specific transcriptional potential. J Neuroimmunol 2012; 248: 2-9.
162. Bruniquel D, Schwartz RH. Selective, stable demethylation of the interleukin-2 gene enhances transcription by an active process. Nat Immunol 2003; 4: 235-40.
163. Casaccia-Bonnefil P, Pandozy G, Mastronardi F. Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesis. Prog Neurobiol 2008; 86: 368-78.
164. Mastronardi FG, Noor A, Wood DD, Paton T, Moscarello MA. Peptidyl argininedeiminase 2 CpG island in multiple sclerosis white matter is hypomethylated. J Neurosci Res 2007; 85: 2006-16.
165. Liu J, Casaccia P. Epigenetic regulation of oligodendrocyte identity. Trends Neurosci 2010; 33: 193-201.
166. Gray SG, Dangond F. Rationale for the use of histone deacetylase inhibitors as a dual therapeutic modality in multiple sclerosis. Epigenetics 2006; 1: 67-75.
167. Faraco G, Cavone L, Chiarugi A. The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis. Mol Med 2011; 17: 442-7.
168. Shuttleworth SJ, Bailey SG, Townsend PA. Histone Deacetylase inhibitors: new promise in the treatment of immune and inflammatory diseases. Curr Drug Targets 2010; 11: 1430-8.
169. Camelo S, Iglesias AH, Hwang D, et al. Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol 2005; 164: 10-21.
170. Qureshi IA, Mehler MF. Emerging role of epigenetics in stroke: part 1: DNA methylation and chromatin modifications. Arch Neurol 2010; 67: 1316-22.
171. Qureshi IA, Mehler MF. The emerging role of epigenetics in stroke: III. Neural stem cell biology and regenerative medicine. Arch Neurol 2011; 68: 294-302.
172. Manev H, Dzitoyeva S, Chen H. Mitochondrial DNA: A Blind Spot in Neuroepigenetics. Biomol Concepts 2012; 3: 107-115.